In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration.

Abstract

Targeted genome editing via engineered nucleases is an exciting area of biomedical research and holds potential for clinical applications. Despite rapid advances in the field, in vivo targeted transgene integration is still infeasible because current tools are inefficient, especially for non-dividing cells, which compose most adult tissues. This poses a… (More)
DOI: 10.1038/nature20565

Topics

Cite this paper

@article{Suzuki2016InVG, title={In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration.}, author={Keiichiro Suzuki and Yuji Tsunekawa and Reyna Hern{\'a}ndez-Ben{\'i}tez and Jun Wu and Jie Zhu and Euiseok Kim and Fumiyuki Hatanaka and Mako Yamamoto and Toshikazu Araoka and Zhe Li and Masakazu Kurita and Tomoaki Hishida and Mo Li and Emi Aizawa and Shicheng Guo and Song Chen and April Goebl and Rupa Devi Soligalla and Jing Qu and T. Jiang and Xin Fu and Maryam Jafari and Concepci{\'o}n Rodr{\'i}guez Esteban and William Travis Berggren and J. Rafael Lajara and Estrella N{\'u}{\~n}ez-Delicado and Pedro Bueso Guill{\'e}n and Josep Mar{\'i}a Campistol and Fumio Matsuzaki and Guang-Hui Liu and Pierre Magistretti and Kun Zhang and Edward M. Callaway and Kang Zhang and Juan Carlos I. Belmonte}, journal={Nature}, year={2016}, volume={540 7631}, pages={144-149} }